Trials / Unknown
UnknownNCT05353192
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
A Multicenter, Open-label, Single Arm Phase IV Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 2 Years – 10 Years
- Healthy volunteers
- Not accepted
Summary
To Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children with Achondroplasia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant human growth hormone | Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks |
Timeline
- Start date
- 2022-09-23
- Primary completion
- 2025-02-01
- Completion
- 2025-02-01
- First posted
- 2022-04-29
- Last updated
- 2023-02-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05353192. Inclusion in this directory is not an endorsement.